Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02141282
Recruitment Status : Active, not recruiting
First Posted : May 19, 2014
Last Update Posted : June 3, 2019
Sponsor:
Collaborator:
Roche-Genentech
Information provided by (Responsible Party):
AbbVie

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 8, 2021
Estimated Study Completion Date : December 8, 2021